Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07764263
Contextualizing Care for Patients With a Serious IllnessRadboud University Medical CenterCompletedNot Applicable
NCT07764263Completed
Not Applicable
Contextualizing Care for Patients With a Serious IllnessRadboud University Medica...
NCT07762820
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder TumorsLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07762820Not Yet Recruiting
Not Applicable
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retr...Ludwig-Maximilians - Univ...
NCT07763938
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell MalignanciesNanjing Legend Biotech Co.Not Yet RecruitingPhase 1
NCT07763938Not Yet Recruiting
Phase 1
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relap...Nanjing Legend Biotech Co...
NCT07764250
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive ImpairmentShifa Tameer-e-Millat UniversityRecruitingNot Applicable
NCT07764250Recruiting
Not Applicable
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training i...Shifa Tameer-e-Millat Uni...
NCT07762872
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in the Early Treatment of Attacks in NMOSDChifeng Municipal HospitalRecruiting
NCT07762872Recruiting
—
A Multicenter Prospective Real-World Effectiveness and Safety of Satralizumab in...Chifeng Municipal Hospita...
NCT07763964
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763964Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07764081
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764081Recruiting
—
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, N...
NCT07763249
Comparison of Paravertebral Versus Epidural Block for Post-thoracotomy Pain ControlHospital de Clinicas de Porto AlegreNot Yet RecruitingNot Applicable
NCT07763249Not Yet Recruiting
Not Applicable
Comparison of Paravertebral Versus Epidural Block for Post-thoracotomy Pain Cont...Hospital de Clinicas de P...
NCT07762586
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NAC)Rutgers, The State University of New JerseyRecruitingPhase 2
NCT07762586Recruiting
Phase 2
Luminal Bladder Cancer Effective Response to Neoadjuvant Chemotherapy (LUMBER-NA...Rutgers, The State Univer...
NCT07764172
Sarcopenia in Acute Ischemic StrokeUniversity Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba)Recruiting
NCT07763613
Clinical Evaluation of the Pelvic Floor Fatigue Index (PFFI)Trabzon Kanuni Education and Research HospitalNot Yet Recruiting
NCT07763613Not Yet Recruiting
—
Clinical Evaluation of the Pelvic Floor Fatigue Index (PFFI)Trabzon Kanuni Education...
NCT07762794
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairHumacyte, Inc.Not Yet RecruitingPhase 4
NCT07762794Not Yet Recruiting
Phase 4
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Worl...Humacyte, Inc.
NCT07763704
The Impact of Tonsillectomy Techniques on Secondary Tonsillectomy BleedingAssiut UniversityNot Yet Recruiting
NCT07763704Not Yet Recruiting
—
The Impact of Tonsillectomy Techniques on Secondary Tonsillectomy BleedingAssiut University
NCT07762729
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up StudyChildren's Hospital of Fudan UniversityEnrolling By Invitation
NCT07762729Enrolling By Invitation
—
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up...Children's Hospital of Fu...
NCT07762768
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Response in Individuals With PrediabetesCSIR National Institute for Interdisciplinary Science and Technology (NIIST), ThiruvananthapuramNot Yet RecruitingNot Applicable
NCT07762768Not Yet Recruiting
Not Applicable
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Res...CSIR National Institute f...
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
Result Breakdown
Not yet recruiting9 (45%)
Recruiting7 (35%)
Completed3 (15%)
Enrolling by invitation1 (5%)
Not Specified7 (35%)
not_applicable7 (35%)
Phase 23 (15%)
Phase 12 (10%)
Phase 41 (5%)